Phase 4 N=42 Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
Smoking Cessation · Schizophrenia
Primary: Exhaled Carbon Monoxide (CO) as Parts Per Million (PPM) — 11.5; 12.3; 12.0; 7.8 ppm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=55 A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
Pandemic Influenza Prevention
Primary: Seroprotection Rate as Measured by Single Radial Hemolysis (SRH) Antibody Titer for the Vaccine Strain at 21 Days After the Second Vaccination — 32.7 Percentage of…
Phase 4 N=54 Investigation of Sugammadex in Outpatient Urological Procedures
Malignant Neoplasms of Urinary Tract · Bladder Cancer
Primary: Muscle Recovery Time — 2; 9.24 minutes
Phase 4 N=475 A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )
Hepatitis E
Primary: Number of Participants Whose Anti-HEV Antibody Seroconverted at One Month After The Third Dose — 188; 196 Participants
Phase 4 N=32 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Signal Change in Brain Activity in the Amygdala When Viewing Emotional Faces — .1489; .1074; .0119; .1404 Percent signal change in brain acitivity
Phase 4 N=307 A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
Central Precocious Puberty
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 252 participants
Phase 4 N=546 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms — 115; 58; 4; 0 Participants
Phase 4 N=500 Advancing Tobacco Use Treatment for African American Smokers
Smoking Cessation
Primary: Number of Participants With Smoking Abstinence at Month 6 — 47; 13 Participants
Phase 4 N=259 Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score in 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Post-randomization — 0.538; -0.075 Score on a scale…
Phase 4 N=90 Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD
COPD
Primary: Change in Lung Function (FEV1) — 0.05; -0.05 litres
Phase 4 N=64 Progesterone Augmentation of Nicotine Replacement Therapy Study
Smoking Cessation
Primary: 7-day Point Prevalence of Smoking Abstinence — 8; 11; 25; 20 Participants — p=0.3253
Phase 4 N=50 Botox Cosmetic and the Young Patient With Glabellar Furrows
Glabellar Furrows
Primary: Reduction of the Facial Wrinkle Scale — 1.86; 2.10 units on a scale — p=<.001
Phase 4 N=363 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
Macular Degeneration
Primary: Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to Month 12 — -4.8; -0.9 ETDRS Letters
Phase 4 N=26 The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy
Insomnia · Major Depressive Disorder
Primary: Change From Baseline in Actigraphy-Measured Sleep Latency at the End of the Treatment Period — -6.81 minutes — p=0.2955
Phase 4 N=23 Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting
Hemophilia A
Primary: Percentage of Participants Who Developed Clinically Significant Factor VIII (FVIII) Inhibitors During the Course of the Study — 21.74 Percentage of participants